The Interplay Between Cardiovascular Disease and Lung Cancer

• Published in: Curēus (Palo Alto, CA) Vol. 16; no. 6; p. e62953
• Main Authors: Katic, Luka, Choi, James, Diaz Saravia, Sara, Silverman, Alexander, Nagourney, Alexander, Torelli, Vincent, Gupta, Soumya, Glavan, Martina, Gulati, Amit, Khurana, Sakshi, Tsyvkin, Elina
• Format: Journal Article
• Language: English
• Published: United States Cureus Inc 23.06.2024; Cureus
• Subjects: Angina pectoris; Beta blockers; Cancer therapies; Cardiac arrhythmia; Cardiology; Cardiovascular disease; Cardioversion; Chronic illnesses; Congenital diseases; Coronary vessels; Coronaviruses; COVID-19; Diabetes; Heart failure; Hyperlipidemia; Hypertension; Ischemia; Lung cancer; Medical imaging; Mortality; Oncology; Peptides; Risk factors; Side effects; Thyroid diseases; Vein & artery diseases; lung cancer; shared risk factors; cardiovascular disease; cancer treatment complications; multidisciplinary care
• ISSN: 2168-8184; 2168-8184
• DOI: 10.7759/cureus.62953

Cardiovascular disease (CVD) and lung cancer are among the leading causes of mortality worldwide, with a significant interplay that complicates patient management and treatment outcomes. This review explores the complex relationship between various forms of CVD - such as coronary artery disease, heart failure (HF), arrhythmias, and valvular heart disease - and lung cancer. Shared risk factors, including smoking, aging, and chronic inflammation, contribute to the co-occurrence of these conditions. Additionally, treatments for lung cancer, particularly chemotherapy and radiation therapy, can exacerbate CVD, necessitating a multidisciplinary approach to patient care. We delve into specific CVD-related impacts on lung cancer prognosis and vice versa, examining mechanisms, clinical outcomes, and management strategies. Our findings highlight the need for integrated care involving oncologists, cardiologists, and other healthcare providers to optimize treatment plans and improve patient outcomes. Emphasizing comprehensive cardiovascular risk management in lung cancer patients, we advocate for further research to deepen our understanding and develop novel therapeutic approaches, ultimately enhancing the quality of life and survival rates in patients suffering from both CVD and lung cancer.